Colin Bristow

Stock Analyst at UBS

(0)
# 4702
Out of 5,270 analysts
89
Total ratings
24.32%
Success rate
-19.58%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
enGene Holdings
Downgrades: Neutral
34 7
6.06 15.51% 2 Feb 14, 2025
ALX Oncology Holding...
Maintains: Buy
4 3
1.03 113.59% 5 Jan 27, 2025
Pfizer
Maintains: Neutral
31 29
26.02 11.45% 8 Jan 8, 2025
Merck & Co
Maintains: Buy
125 120
92.7 29.45% 6 Jan 8, 2025
PTC Therapeutics
Maintains: Strong Buy
47 71
53.26 33.31% 3 Dec 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
70 96
115.85 -17.13% 3 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
562 586
488.13 20.05% 13 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
335 326
309.49 5.33% 7 Oct 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
234 202
142.16 42.09% 10 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
14 6
1.18 408.47% 3 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 41
18.65 119.84% 5 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
56 16
4.44 260.36% 5 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1090 1099
687.82 59.78% 1 Apr 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
56 54
9.04 497.35% 2 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
164 167
101.28 64.89% 5 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
428 420
927.19 -54.7% 1 Dec 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
12 2
8.12 -75.37% 2 Dec 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
1.14 1478.95% 1 Oct 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
154 146
211.25 -30.89% 2 Aug 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
73 75
59.63 25.78% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
64 26
2.42 974.38% 1 Apr 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
9
8.12 10.84% 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
195
n/a n/a 2 Feb 1, 2021